Literature DB >> 21397958

Transnasal endoscopic management of recurrent juvenile nasopharyngeal angiofibroma.

Asser A El Sharkawy1, Shawky M Elmorsy.   

Abstract

OBJECTIVES: The purpose of this study was to present our experience with definitive endoscopic surgical management of the recurrent juvenile nasopharyngeal angiofibroma. STUDY
DESIGN: Retrospective study.
SETTING: Tertiary care centre.
MATERIALS AND METHODS: This study includes 13 male adolescence patients with recurrent nasopharyngeal angiofibroma who received treatment at our centre between 2005 and 2010. The patient age ranged from 12 to 21 years (mean age, 15.7 years). Endoscopic two surgeons' technique had been used. Follow up MRI every four months.
RESULTS: Complete removal of the recurrent tumor was achieved in 10 cases. Three patients had incomplete removal with further recurrences. These recurrences were two in lateral wall of the sphenoid sinus (2 patients), and soft palate (one patient).
CONCLUSION: Recurrent JNAs are residual disease resulting from incomplete removal of the primary tumor. Transnasal endoscopic sinus surgery is an effective method for treating recurrent JNA. Follow up is essential and integral point in management of JNAs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397958     DOI: 10.1016/j.ijporl.2011.01.033

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  2 in total

Review 1.  Endoscopic treatment of juvenile nasopharyngeal angiofibromas: our experience and review of the literature.

Authors:  G Fyrmpas; I Konstantinidis; J Constantinidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-26       Impact factor: 2.503

2.  Endoscopic transnasal management of inverted papilloma involving frontal sinuses.

Authors:  Tomasz Gotlib; Antoni Krzeski; Marta Held-Ziółkowska; Kazimierz Niemczyk
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-09-29       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.